Your browser doesn't support javascript.
loading
Safety and feasibility of 1 month of daily rifapentine plus isoniazid to prevent tuberculosis in children and adolescents: a prospective cohort study.
Malik, Amyn A; Farooq, Saira; Jaswal, Maria; Khan, Hiba; Nasir, Kumail; Fareed, Usama; Shahbaz, Shumail; Amanullah, Farhana; Safdar, Nauman; Khan, Aamir J; Keshavjee, Salmaan; Becerra, Mercedes C; Hussain, Hamidah.
Afiliación
  • Malik AA; Global Health Directorate, Indus Health Network, Karachi, Pakistan; Interactive Research and Development Global, Singapore; Yale School of Medicine and Yale Institute for Global Health, Yale University, New Haven, CT, USA. Electronic address: amyn.malik@ird.global.
  • Farooq S; Global Health Directorate, Indus Health Network, Karachi, Pakistan.
  • Jaswal M; Global Health Directorate, Indus Health Network, Karachi, Pakistan.
  • Khan H; Global Health Directorate, Indus Health Network, Karachi, Pakistan.
  • Nasir K; Global Health Directorate, Indus Health Network, Karachi, Pakistan.
  • Fareed U; Global Health Directorate, Indus Health Network, Karachi, Pakistan.
  • Shahbaz S; Global Health Directorate, Indus Health Network, Karachi, Pakistan.
  • Amanullah F; The Indus Hospital, Karachi, Pakistan.
  • Safdar N; Global Health Directorate, Indus Health Network, Karachi, Pakistan.
  • Khan AJ; Interactive Research and Development Global, Singapore; Harvard Medical School, Boston, MA, USA; Harvard Medical School Center for Global Health Delivery, Boston, MA, USA.
  • Keshavjee S; Harvard Medical School, Boston, MA, USA; Harvard Medical School Center for Global Health Delivery, Boston, MA, USA; Division of Global Health Equity, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
  • Becerra MC; Harvard Medical School, Boston, MA, USA; Harvard Medical School Center for Global Health Delivery, Boston, MA, USA; Partners In Health, Boston, MA, USA; Division of Global Health Equity, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
  • Hussain H; Interactive Research and Development Global, Singapore.
Lancet Child Adolesc Health ; 5(5): 350-356, 2021 05.
Article en En | MEDLINE | ID: mdl-33770510
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Rifampin / Tuberculosis / Cumplimiento y Adherencia al Tratamiento / Duración de la Terapia / Isoniazida / Antituberculosos Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies País/Región como asunto: Asia Idioma: En Revista: Lancet Child Adolesc Health Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Rifampin / Tuberculosis / Cumplimiento y Adherencia al Tratamiento / Duración de la Terapia / Isoniazida / Antituberculosos Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies País/Región como asunto: Asia Idioma: En Revista: Lancet Child Adolesc Health Año: 2021 Tipo del documento: Article